- Home
- GOOD vs ADPT Comparison
GOOD vs ADPT Comparison
Compare GOOD & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOOD
- ADPT
- Stock Information
- Founded
- GOOD 2003
- ADPT 2009
- Country
- GOOD United States
- ADPT United States
- Employees
- GOOD N/A
- ADPT N/A
- Industry
- GOOD Real Estate Investment Trusts
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOOD Real Estate
- ADPT Health Care
- Exchange
- GOOD Nasdaq
- ADPT Nasdaq
- Market Cap
- GOOD 775.6M
- ADPT 929.8M
- IPO Year
- GOOD N/A
- ADPT 2019
- Fundamental
- Price
- GOOD $16.04
- ADPT $6.39
- Analyst Decision
- GOOD Buy
- ADPT Buy
- Analyst Count
- GOOD 2
- ADPT 4
- Target Price
- GOOD $15.25
- ADPT $6.75
- AVG Volume (30 Days)
- GOOD 299.7K
- ADPT 1.4M
- Earning Date
- GOOD 11-04-2024
- ADPT 02-12-2025
- Dividend Yield
- GOOD 7.48%
- ADPT N/A
- EPS Growth
- GOOD N/A
- ADPT N/A
- EPS
- GOOD 0.21
- ADPT N/A
- Revenue
- GOOD $147,922,000.00
- ADPT $177,282,000.00
- Revenue This Year
- GOOD N/A
- ADPT $6.48
- Revenue Next Year
- GOOD $1.84
- ADPT $18.84
- P/E Ratio
- GOOD $77.13
- ADPT N/A
- Revenue Growth
- GOOD N/A
- ADPT N/A
- 52 Week Low
- GOOD $11.89
- ADPT $2.28
- 52 Week High
- GOOD $17.88
- ADPT $7.07
- Technical
- Relative Strength Index (RSI)
- GOOD 32.37
- ADPT 56.16
- Support Level
- GOOD $16.35
- ADPT $5.81
- Resistance Level
- GOOD $16.83
- ADPT $6.93
- Average True Range (ATR)
- GOOD 0.37
- ADPT 0.50
- MACD
- GOOD -0.16
- ADPT -0.04
- Stochastic Oscillator
- GOOD 24.46
- ADPT 46.35
About GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).